APM Valuation

Aptorum Group Ltd

Add to Watchlist

Advanced Chart

1.360

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

APM Relative Valuation

APM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, APM is overvalued; if below, it's undervalued.

Historical Valuation

Aptorum Group Ltd (APM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.05 is considered Undervalued compared with the five-year average of -1.57. The fair price of Aptorum Group Ltd (APM) is between 186.47 to 187.19 according to relative valuation methord. Compared to the current price of 1.38 USD , Aptorum Group Ltd is Undervalued By 99.26%.

Relative Value

Fair Zone

186.47-187.19

Current Price：1.38

99.26%

Undervalued

0.02

Trailing

Forward

0.20

EV/EBITDA

Aptorum Group Ltd. (APM) has a current EV/EBITDA of 0.20. The 5-year average EV/EBITDA is -3.69. The thresholds are as follows: Strongly Undervalued below -24.50, Undervalued between -24.50 and -14.10, Fairly Valued between 6.71 and -14.10, Overvalued between 6.71 and 17.11, and Strongly Overvalued above 17.11. The current Forward EV/EBITDA of 0.20 falls within the Historic Trend Line -Fairly Valued range.

0.01

EV/EBIT

Aptorum Group Ltd. (APM) has a current EV/EBIT of 0.01. The 5-year average EV/EBIT is -1.35. The thresholds are as follows: Strongly Undervalued below -4.85, Undervalued between -4.85 and -3.10, Fairly Valued between 0.40 and -3.10, Overvalued between 0.40 and 2.15, and Strongly Overvalued above 2.15. The current Forward EV/EBIT of 0.01 falls within the Historic Trend Line -Fairly Valued range.

0.04

Aptorum Group Ltd. (APM) has a current PS of 0.04. The 5-year average PS is 23.56. The thresholds are as follows: Strongly Undervalued below -41.13, Undervalued between -41.13 and -8.79, Fairly Valued between 55.90 and -8.79, Overvalued between 55.90 and 88.24, and Strongly Overvalued above 88.24. The current Forward PS of 0.04 falls within the Historic Trend Line -Fairly Valued range.

0.05

P/OCF

Aptorum Group Ltd. (APM) has a current P/OCF of 0.05. The 5-year average P/OCF is -1.53. The thresholds are as follows: Strongly Undervalued below -4.83, Undervalued between -4.83 and -3.18, Fairly Valued between 0.13 and -3.18, Overvalued between 0.13 and 1.78, and Strongly Overvalued above 1.78. The current Forward P/OCF of 0.05 falls within the Historic Trend Line -Fairly Valued range.

0.05

P/FCF

Aptorum Group Ltd. (APM) has a current P/FCF of 0.05. The 5-year average P/FCF is -1.67. The thresholds are as follows: Strongly Undervalued below -5.25, Undervalued between -5.25 and -3.46, Fairly Valued between 0.12 and -3.46, Overvalued between 0.12 and 1.90, and Strongly Overvalued above 1.90. The current Forward P/FCF of 0.05 falls within the Historic Trend Line -Fairly Valued range.

Aptorum Group Ltd (APM) has a current Price-to-Book (P/B) ratio of 0.37. Compared to its 3-year average P/B ratio of 0.72 , the current P/B ratio is approximately -48.75% higher. Relative to its 5-year average P/B ratio of 1.50, the current P/B ratio is about -75.39% higher. Aptorum Group Ltd (APM) has a Forward Free Cash Flow (FCF) yield of approximately -11.41%. Compared to its 3-year average FCF yield of -67.92%, the current FCF yield is approximately -83.21% lower. Relative to its 5-year average FCF yield of -49.26% , the current FCF yield is about -76.84% lower.

0.37

P/B

Median3y

0.72

Median5y

1.50

-11.98

FCF Yield

Median3y

-67.92

Median5y

-49.26

Competitors Valuation Multiple

The average P/S ratio for APM's competitors is 27.21, providing a benchmark for relative valuation. Aptorum Group Ltd Corp (APM) exhibits a P/S ratio of 0.04, which is -99.84% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Bolt Biotherapeutics Inc

Addex Therapeutics Ltd

Aprea Therapeutics Inc

Kiora Pharmaceuticals Inc

2.68

-100.00%

9.89M

Performance Decomposition

Market capitalization of APM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of APM in the past 1 year is driven by Unknown.